TRx Biosciences

TRx Biosciences is developing a disruptive oral drug delivery platform designed to overcome fundamental limitations in drug absorption and targeting. Its technology leverages an unexploited physiological uptake channel, utilizing chylomicrons to enhance systemic absorption, avoid first-pass metabolism, and direct therapeutics to sites like the brain and tumors. The company is advancing a portfolio of co-development and wholly-owned programs with the goal of transforming the efficacy and development of small molecule therapies.

A three-tiered oral drug delivery platform that exploits an unexploited intestinal uptake channel (likely lymphatic/chylomicron pathway) to enhance absorption, avoid first-pass metabolism, and direct small molecule therapeutics to specific tissues like the brain and tumors, with additional immunomodulatory potential.

TRx competes in the advanced drug delivery space against companies developing lipid nanoparticles, polymer-based carriers, and other targeted delivery technologies. Its claimed differentiation lies in leveraging a specific, natural biological pathway (chylomicrons) for systemic targeting, which may offer advantages in manufacturability and immune system engagement compared to synthetic carriers.